Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in non-diabetic chronic kidney disease
NCT05047263Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of finerenone in chronic kidney disease (CKD), sponsored by Bayer. Started Sep 2021; status: completed.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05047263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047263.